Ocular surface applied medicament for treating eyes immunological disease and inhibiting proliferation and neovascularization

Abstract

The present invention relates to an ocular surface applied medicament for treating drug used for treating eyes immunological disease and inhibiting proliferation and neovascularization, wherein rapamycin is used as active component at 0.01-2% by weight. And the ocular surface applied medicament provided by the present invention can be used for treating syndrome, allergic conjunctivitis, giant papillary conjunctivitis, vernal conjunctivitis, atopic keratoconjunctivitis, pterygium, Mooren ulcer, Stevens Johnson syndrome, dry eye, scleritis, episcleritis, various tunicauveae inflammation and the like, and also can be used for treating eye trauma after cornea transplanting and preventing fibrogenesis, adhesion, and cicatrisation, and inhibiting neovascularization after operation.

Description

Technical field:

[0001] The present invention relates to ophthalmic pharmaceutical preparations, and in particular provides an ocular surface drug that uses rapamycin as the main active ingredient to treat ocular immune diseases, treat ocular immune diseases, and inhibit proliferation and neovascularization. Drug. Background technique:

[0002] Ocular immune disease is a refractory eye disease in ophthalmology. At present, the topical ophthalmic drugs mainly include corticosteroids and cyclosporine A. On the one hand, some diseases cannot be effectively controlled. On the other hand, long-term application of corticosteroids can cause glaucoma and cataracts. , secondary infection and other serious hazards to eye health. Immune rejection after keratoplasty is also an immune disease in a broad sense. Corneal transplantation is an important sight restoration operation for corneal blindness, and it is also the main measure for treating some stubborn corneal lesions. Of all orga...